CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Everfront Biotech Holding Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Everfront Biotech Holding Co Ltd
No. 130, Songshan Rd., Xinyi Dist, 10F-1
Phone: +886 225501449p:+886 225501449 TAIPEI, 103  Taiwan
Business Summary
Everfront Biotech Holding Co Ltd is primarily engaged in biotechnology research and development services. The Company's mission is to construct effective strategies for combating hard-to-treat diseases such as glioblastoma (GBM), pancreatic cancer (PC), and amyotrophic lateral sclerosis (ALS). The Company designed the implantable Cerebraca Wafer for in-situ drug delivery. After surgical resection, implantation of the wafer at the tumor margin is designed to create a localized high drug concentration, targeting residual and or unresectable tumor cells. Additionally, the wafer's sustained release technology is designed to facilitate continuous drug release within the brain for one month. The Company also developed soft-gel capsules designed to be easily swallowed as maintenance therapy following Cerebraca Wafer implantation. Product pipelines include Cerebraca Wafer, EF-009 Wafer, HK-001, EF-031.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer Tza-ZenChaung 72 1/1/2023 1/1/2023
Founder, Director Ho-ChingChen 67
Chief Financial Officer Pi-ChuanChien 56 2/1/2023 2/1/2023
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 16 (As of 12/31/2023)


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 28, 2025